Summary
Biogen Inc. filed an 8-K on October 25, 2022, to report its financial results for the third quarter ended September 30, 2022. The primary purpose of this filing is to furnish the press release announcing these results, which provides investors with key performance metrics and financial condition updates. Investors should review the press release for details on revenue, profitability, and any significant business developments during the quarter.
Key Highlights
- 1Biogen announced its Q3 2022 financial results via a press release filed with the SEC on October 25, 2022.
- 2The filing incorporates the press release by reference, providing detailed operational and financial data.
- 3Investors can find information on revenue, earnings, and other key financial metrics for the third quarter.
- 4The press release is furnished, not filed, meaning it does not subject Biogen to Section 18 of the Exchange Act liabilities.
- 5This 8-K serves as the official notification of the company's quarterly performance and financial standing as of September 30, 2022.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Biogen Inc.'s financial results for the third quarter ended September 30, 2022, by furnishing the press release that contains this information.
The specific financial details, including revenue and earnings, are contained within the press release dated October 25, 2022, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.
No, the press release is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means Biogen does not assume liabilities under that section for the information in the press release.